Abstract
Glioblastoma (GBM) represents the most common and aggressive histologic subtype among malignant astrocytoma and is associated with poor outcomes because of heterogeneous tumour cell population including mature non-stem-like cell and immature stem-like cells within the tumour. Thus, it is critical to find new target-specific therapeutic modalities. Protein arginine methyltransferase enzyme 5 (PRMT5) regulates many cellular processes through its methylation activity and its overexpression in GBM is associated with more aggressive disease. Previously, we have shown that silencing of PRMT5 expression in differentiated GBM cell lines results in apoptosis and reduced tumour growth in mice. Here, we report the critical role of PRMT5 in GBM differentiated cells (GBMDC) grown in serum and GBM neurospheres (GBMNS) grown as neurospheres in vitro. Our results uncover a very significant role for PRMT5 in GBMNS self-renewal capacity and proliferation. PRMT5 knockdown in GBMDC led to apoptosis, knockdown in GBMNS led to G1 cell cycle arrest through upregulation of p27 and hypophoshorylation of retinoblastoma protein, leading to senescence. Comparison of impact of PRMT5 on cellular signalling by the Human Phospho-Kinase Array and chromatin immunoprecipitation-PCR revealed that unlike GBMDC, PRMT5 regulates PTEN expression and controls Akt and ERk activity in GBMNS. In vivo transient depletion of PRMT5 decreased intracranial tumour size and growth rate in mice implanted with both primary tumour-derived GBMNS and GBMDC. This is the first study to identify PTEN as a potential downstream target of PRMT5 and PRMT5 is vital to support both mature and immature GBM tumour cell populations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26: 756–784.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459–466.
Masui K, Cloughesy TF, Mischel PS . Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012; 38: 271–291.
Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16: 2443–2449.
Scoumanne A, Zhang J, Chen X . PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res 2009; 37: 4965–4976.
Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 2009; 16: 304–311.
Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S . Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 2004; 24: 9630–9645.
Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res 2014; 74: 1752–1765.
Han X, Li R, Zhang W, Yang X, Wheeler CG, Friedman GK et al. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J Neurooncol 2014; 118: 61–72.
Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012; 338: 1080–1084.
Karberg S . Switching on epigenetic therapy. Cell 2009; 139: 1029–1031.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807–1812.
Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391–403.
Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S et al. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem Cells 2013; 31: 870–881.
Weinberg RA . The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–330.
Adams PD, Kaelin WG Jr. . Transcriptional control by E2F. Semin Cancer Biol 1995; 6: 99–108.
Qian Y, Luckey C, Horton L, Esser M, Templeton DJ . Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol Cell Biol 1992; 12: 5363–5372.
Stevaux O, Dyson NJ . A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol 2002; 14: 684–691.
Dahiya A, Wong S, Gonzalo S, Gavin M, Dean DC . Linking the Rb and polycomb pathways. Mol Cell 2001; 8: 557–569.
Vandel L, Nicolas E, Vaute O, Ferreira R, Ait-Si-Ali S, Trouche D . Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol Cell Biol 2001; 21: 6484–6494.
Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ . Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331–342.
Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM . Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73: 487–497.
Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA . Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70: 993–1006.
Sherr CJ, Roberts JM . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501–1512.
Hengst L, Reed SI . Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 1998; 227: 25–41.
Maehama T, Dixon JE . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375–13378.
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29–39.
Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science 2013; 341: 399–402.
Goldstein S . Replicative senescence: the human fibroblast comes of age. Science 1990; 249: 1129–1133.
Sherwood SW, Rush D, Ellsworth JL, Schimke RT . Defining cellular senescence in IMR-90 cells: a flow cytometric analysis. Proc Natl Acad Sci USA 1988; 85: 9086–9090.
Cristofalo VJ, Phillips PD, Sorger T, Gerhard G . Alterations in the responsiveness of senescent cells to growth factors. J Gerontol 1989; 44: 55–62.
Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363–9367.
Shay JW, Pereira-Smith OM, Wright WE . A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991; 196: 33–39.
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821–5828.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396–401.
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756–760.
Nardella C, Clohessy JG, Alimonti A, Pandolfi PP . Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11: 503–511.
Wu CH, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW . Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA 2007; 104: 13028–13033.
Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464: 374–379.
Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010; 120: 681–693.
Tan W, Gu Z, Shen B, Jiang J, Meng Y, Da Z et al. PTEN/Akt-p27(kip1) signaling promote the BM-MSCs senescence and apoptosis in SLE patients. J Cell Biochem 2015; 116: 1583–1594.
Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, Lee BL et al. PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 2011; 18: 666–677.
Ali IU, Schriml LM, Dean M . Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91: 1922–1932.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943–1947.
McDowell KA, Riggins GJ, Gallia GL . Targeting the AKT pathway in glioblastoma. Curr Pharm Des 2011; 17: 2411–2420.
Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008; 16: 1546–1555.
Acknowledgements
This study was financially supported by: Kaur: NIH RO1 (CA150153), NIH P01 (CA163205), NIH P30 (NS045758), NIH RO1 (NS064607); Baiocchi: NIH R21 NS071346 and Yoo: IRG-67-003-50.
Author contributions
Conception and design: YK Banasavadi-Siddegowda, B Kaur and R Baiocchi. Development of methodology: YK Banasavadi-Siddegowda. Acquisition of data: YK Banasavadi-Siddegowda, L Russell, E Frair, Vrajesh A Karkhanis, T Relation and J Yoo. Analysis and interpretation of data: YK Banasavadi-Siddegowda, B Kaur, R Baiocchi, J Zhang and J Imitola. Writing, review and/or revision of manuscript: YK Banasavadi-Siddegowda, B Kaur and R Baiocchi.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Banasavadi-Siddegowda, Y., Russell, L., Frair, E. et al. PRMT5–PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells. Oncogene 36, 263–274 (2017). https://doi.org/10.1038/onc.2016.199
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2016.199
This article is cited by
-
PRMT1 in human neoplasm: cancer biology and potential therapeutic target
Cell Communication and Signaling (2024)
-
Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks
Journal of Experimental & Clinical Cancer Research (2024)
-
Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma
Nature Communications (2023)
-
Amino acid metabolism in health and disease
Signal Transduction and Targeted Therapy (2023)
-
Critical Roles of Protein Arginine Methylation in the Central Nervous System
Molecular Neurobiology (2023)